Trexquant Investment LP Adaptimmune Therapeutics PLC Transaction History

Trexquant Investment LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$3.5 - $5.68 $82,631 - $134,099	-23,609 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$3.44 - $6.37 $81,214 - $150,389	23,609 New	23,609 $122,000
Q2 2021 Aug 12, 2021	SELL	$3.86 - $5.78 $180,424 - $270,168	-46,742 Closed	0 $0
Q1 2021 May 13, 2021	BUY	$4.9 - $6.83 $229,035 - $319,247	46,742 New	46,742 $248,000
Q3 2018 Nov 09, 2018	SELL	$8.27 - $13.56 $124,223 - $203,684	-15,021 Closed	0 $0
Q2 2018 Aug 07, 2018	BUY	$10.42 - $13.74 $156,518 - $206,388	15,021 New	15,021 $178,000
Q1 2018 May 03, 2018	SELL	$7.1 - $11.56 $192,502 - $313,426	-27,113 Closed	0 $0
Q4 2017 Feb 09, 2018	BUY	$6.68 - $8.74 $181,114 - $236,967	27,113	27,113 $181,000

123M

34.2K

16.3K

Ticker ADAP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 163,370,000
Market Cap $35.9M
Description
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...

Get notified when there are updates to the investment portfolio of Trexquant Investment LP, based on Form 13F filings with the SEC.

Stay updated on Trexquant Investment LP with notifications on news.